摘要
阿尔茨海默病 (AD) 是全球最常见和最严重的年龄依赖性神经退行性疾病。尽管有大量研究致力于阐明这种病理学并开发有效药物,但该疾病的多方面性质和复杂性无疑是迄今为止无法治愈的原因。目前使用的药物主要是通过乙酰胆碱酯酶 (AChE) 抑制来补偿神经递质乙酰胆碱的下降,尽管它们只能提供暂时的对症益处,不能阻止 AD 进展。虽然引发 AD 发病和进展的多种因素尚未完全了解,但已经认识到一些病理特征和潜在途径会导致其病理,例如金属稳态失调、蛋白质错误折叠、氧化应激和神经递质缺乏,其中一些相互关联。因此,最近人们对开发多靶点定向配体 (MTDL) 以与 AD 的几个病理靶点同时相互作用产生了广泛的兴趣。在这篇综述中,介绍了一些关于具有多功能的 MTDL 金属螯合剂的最新报告(2016 年至今)。这些化合物能够击中多种 AD 靶点或途径,例如调节特定的生物金属离子(例如 Cu、Fe、Zn)和蛋白质错误折叠(β-淀粉样蛋白和 tau 蛋白)、抗氧化活性和 AChE 抑制。与原始参考化合物相比,对这些杂合体的特性进行了讨论,鉴于 AD 治疗中的有效潜在应用,一些 MTDL 被概述为未来研究的主要化合物。
关键词: 阿尔茨海默病、多靶点药物、生物金属、金属螯合剂、Aβ 聚集、AChE 抑制剂、抗氧化特性、药物重新定位。
Current Medicinal Chemistry
Title:Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Volume: 28 Issue: 35
关键词: 阿尔茨海默病、多靶点药物、生物金属、金属螯合剂、Aβ 聚集、AChE 抑制剂、抗氧化特性、药物重新定位。
摘要: Alzheimer´s disease (AD) is the most common and severe age-dependent neurodegenerative disorder worldwide. Notwithstanding the large amount of research dedicated to both the elucidation of this pathology and the development of an effective drug, the multifaceted nature and complexity of the disease are certainly a rationale for the absence of cure so far. Currently available drugs are used, mainly to compensate the decline of the neurotransmitter acetylcholine by acetylcholinesterase (AChE) inhibition, though they only provide temporary symptomatic benefits and cannot stop AD progression. Although the multiple factors that contribute to trigger AD onset and progression are not yet fully understood, several pathological features and underneath pathways have been recognized to contribute to its pathology, such as metal dyshomeostasis, protein misfolding, oxidative stress and neurotransmitter deficiencies, some of them being interconnected. Thus, there is widespread recent interest in the development of multitarget-directed ligands (MTDLs) for simultaneous interaction with several pathological targets of AD. In this review, a selection of the most recent reports (2016-up to present) on metal chelators of MTDLs with multifunctionalities is presented. These compounds enable the hitting of several AD targets or pathways, such as modulation of specific biometal ions (e.g., Cu, Fe, Zn) and of protein misfolding (β-amyloid and tau protein), anti-oxidant activity and AChE inhibition. The properties found for these hybrids are discussed in comparison with the original reference compounds, some MTDLs being outlined as leading compounds for pursuing future studies in view of efficient potential applications in AD therapy.
Export Options
About this article
Cite this article as:
Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity, Current Medicinal Chemistry 2021; 28 (35) . https://dx.doi.org/10.2174/0929867328666210218183032
DOI https://dx.doi.org/10.2174/0929867328666210218183032 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Graphical Abstracts
Current Nanoscience Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Proton Magnetic Resonance Spectroscopy Changes After Antipsychotic Treatment
Current Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design From QTL to Candidate Gene: A Genetic Approach to Alcoholism Research
Current Drug Abuse Reviews New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Synthesis and Cholinesterase Inhibitory Activity of N-Phosphorylated/ N-Tiophosphorylated Tacrine
Medicinal Chemistry Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research High-throughput Screening Identifies Small Molecule Inhibitors of Molecular Chaperones
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Liposome-linear polyethyleneimine-DNA Nanocomplexes for Gene Delivery: Preparation, Characterization and In Vitro Transfection Activity
Current Nanoscience